Company:  ENDOCYTE INC (ECYT)
Form Type:  10-Q
Filing Date:  11/13/2012 
CIK:  0001235007 
Address:  3000 KENT AVE STE A1-100 
City, State, Zip:  WEST LAFAYETTE, Indiana 47906 
Telephone:  (765) 463-7175 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$18.89  
Change: 
-0.25 (-1.31%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$767.99M
Description of Business
We are a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. We use our proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. Our SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. We are also developing companion imaging agents for each of our SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Unaudited Condensed Consolidated Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and ...
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE ...
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO RULE 13a-14(a)/15d-14(a) OF THE ...
  EXHIBIT 32.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
BROKERAGE PARTNERS